14 小时
Mid-Day on MSNOf neurons and normalcy: How epilepsy and the stigma associated with it can impact livesWhen Fatima Sana Shaikh talked about Epilepsy, she shed light on one of the most common neurological disorders worldwide, but one which still carries stigma ...
Join the epilepsy community for Purple Day® on March 26, a global initiative to raise epilepsy awareness and support the millions of people living with epilepsy worldwide. Approximately 65 million ...
This group supports parents and caregivers and provides a place to share experiences, provide encouragement, and offer support for each other through this epilepsy journey. The group takes place on ...
Feb. 19, 2025 — New research focuses on diagnostic delays experienced by people with epilepsy, a neurological disorder characterized by unpredictable seizures that affects over 3 million people ...
Children in England living with a rare and severe form of epilepsy could soon benefit from a new drug being rolled out on the NHS. Fenfluramine has been recommended by the National Institute for ...
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...
Biotech startup Itay & Beyond uses AI analysis of 'brain-on-a-chip' made from stem cells to predict drug efficacy for neuropsychiatric disorders and expedite testing and development ...
A Lancaster teen is making a name for herself on the world billiards stage after a health scare due to epilepsy.
Steve Darling praised the 13-year-old who is pushing to make public transport more accessible for wheelchair users.
At the moment that's nobody." Catherine Cox, from Keyworth in Nottinghamshire, was one of thousands of women who took the epilepsy drug, sodium valproate, while pregnant, something which is now ...
Hundreds of children with severe epilepsy will be able to benefit from a groundbreaking new treatment on the NHS that could significantly reduce their seizures, providing new hope for them and their ...
Pending the outcome of this Phase 3 trial, and supported by ongoing Phase 1/2 trials, the results are intended to be part of a robust data package to support regulatory submission for drug approval.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果